Wang MK, Yu XL, Zhou LY, Si HM, Hui JF, Yang JS. Potential role of vitamin D in patients with diabetes, dyslipidaemia, and COVID-19. World J Crit Care Med 2022; 11(2): 112-114 [PMID: 35433313 DOI: 10.5492/wjccm.v11.i2.112]
Corresponding Author of This Article
Ji-Shun Yang, MD, PhD, Director, Medical Care Center, Naval Medical Center of PLA, Naval Medical University, No. 338 Huaihai West Road, Shanghai 200052, China. jasunyang@foxmail.com
Research Domain of This Article
Nutrition & Dietetics
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang MK, Yu XL, Zhou LY, Si HM, Hui JF, Yang JS. Potential role of vitamin D in patients with diabetes, dyslipidaemia, and COVID-19. World J Crit Care Med 2022; 11(2): 112-114 [PMID: 35433313 DOI: 10.5492/wjccm.v11.i2.112]
Ming-Ke Wang, Xue-Lu Yu, Li-Yun Zhou, Hong-Mei Si, Ju-Fen Hui, Department of Disease Control and Prevention, Naval Medical Center of PLA, Naval Medical University, Shanghai 200052, China
Ji-Shun Yang, Medical Care Center, Naval Medical Center of PLA, Naval Medical University, Shanghai 200052, China
Author contributions: Wang MK wrote the draft; Yu XL, Zhou LY, Si HM, and Hui JF collected the literature; Wang MK and Yang JS conceptualized the article and revised the manuscript; all authors have read and approved the final manuscript.
Supported byMajor Construction Program of Military Key Disciplines during the 13th Five-Year Plan Period, No. 2020SZ21-15.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ji-Shun Yang, MD, PhD, Director, Medical Care Center, Naval Medical Center of PLA, Naval Medical University, No. 338 Huaihai West Road, Shanghai 200052, China. jasunyang@foxmail.com
Received: October 17, 2021 Peer-review started: October 17, 2021 First decision: December 16, 2021 Revised: December 22, 2021 Accepted: February 15, 2022 Article in press: February 15, 2022 Published online: March 9, 2022 Processing time: 136 Days and 10.3 Hours
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 has become a worldwide public health crisis. Studies have demonstrated that diabetes and dyslipidaemia are common comorbidities and could be high-risk factors for severe COVID-19. Vitamin D, a group of fat-soluble compounds responsible for intestinal absorption of calcium, magnesium, and phosphate, has been widely used as a dietary supplement for the prevention and treatment of numerous diseases, including infectious and non-infectious diseases, due to its high cost-effectiveness; safety; tolerability; and anti-thrombotic, anti-inflammatory, antiviral, and immunomodulatory properties. In this letter to the editor, we mainly discuss the potential role of vitamin D in patients with diabetes, dyslipidaemia, and COVID-19.
Core Tip: Diabetes and dyslipidaemia are common comorbidities in patients with coronavirus disease 2019 (COVID-19), and these comorbidities are often associated with worse clinical outcome. In this letter to the editor, we hypothesize that vitamin D may be a prognostic factor and could be a promising preventive measure and treatment for patients with diabetes, dyslipidaemia, and COVID-19.
